Skip to content

Axsome Therapeutics

US · AXSM #1533 by market cap Listed 2015
129.36 -6.32 -4.66%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 134.68 -0.74%
After-hours 129.36 0.00%
Overnight 135.50 -0.13%
255.17129.36129.362026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AXSM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -23.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 6.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D-

The radar needs all six factors. Available grades are shown below.

Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 73.8x Better than 4%
Price / Sales 8.6x Better than 12%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 92.6% Better than 97%
Operating margin -26.5% Better than 11%
Net margin -28.7% Better than 11%
Return on equity -252.1% Better than 2%
Return on invested capital -63.5% Better than 4%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -37.7% Better than 12%
6-month return -45.2% Better than 9%
12-month return (ex latest month) -2.9% Better than 31%
Distance below 52-week high 50.3% Better than 18%
Financial Health D

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.6x Better than 43%
Debt to assets 31.6% Better than 39%
Interest coverage -27.0x Better than 9%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 94.1% Better than 77%
Upside to average target 104.0% Better than 84%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.70%
1M -18.94%
3M -37.82%
6M -43.91%
YTD -29.17%
1Y -9.73%
3Y +115.46%
5Y +261.34%

Key statistics

Price & volume

Prev close
135.68
Open
133.92
Day range
128.23 - 135.09
Avg price
130.33
Volume
811.79K
Turnover
105.80M
Amplitude
5.06%
52-week range
123.00 - 260.19

Valuation

P/E
-35.15
P/E (TTM)
-42.69
P/B
64.55
EPS
-3.68
Net profit
-193.57M
Net assets
105.41M

Share structure

Market cap
6.80B
Float cap
5.78B
Shares out
52.60M
Float shares
44.68M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-11-19
52-week range 5% of range
123.00 260.19

50.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.87M net over the window

Short interest

Shares short
3.26M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Axsome Therapeutics (AXSM)?

Axsome Therapeutics last traded at 129.36. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Axsome Therapeutics's market cap?

About 6.80B.

What is the P/E ratio of Axsome Therapeutics?

The trailing twelve-month P/E is -42.69. The Valuation tab shows it against the stock's own five-year range.

Does Axsome Therapeutics pay a dividend?

Axsome Therapeutics does not currently pay a regular dividend.

Is Axsome Therapeutics a buy according to analysts?

The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 263.94, which implies 104.0% upside from the current price. This is not investment advice.

What is Axsome Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Axsome Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Axsome Therapeutics discussion 0 comments

Add a comment